Literature DB >> 8456438

Rapid DNA typing of class II HLA antigens using the polymerase chain reaction and reverse dot blot hybridization.

I Buyse1, R Decorte, M Baens, H Cuppens, G Semana, M P Emonds, P Marynen, J J Cassiman.   

Abstract

A nonisotopic oligotyping method using reverse dot blot hybridization was developed for HLA class II DQA1, DQB1, DPB1, DRB1, DRB3, DRB4, DRB5 alleles. The polymorphic second exon of the different genes was amplified by the polymerase chain reaction (PCR). For each gene the amplified DNA was hybridized at stringent conditions to membrane-bound sequence-specific oligonucleotides (SSOs) and visualization of positive signals was done by chemiluminescence. A combination of 11, 18, 23 and 31 SSOs was designed to identify 9/13 DQA1, 16/17 DQB1, 23/24 DPB1 and 50/55 DRB1, 4 DRB3, 1 DRB4, 3/4 DRB5 alleles respectively. For the DRB1 locus, an additional DRB1*04 group-specific PCR was developed to make discrimination between the DR4 alleles possible in different heterozygous combinations. The procedure described here provides rapid and nonisotopic genotyping of heterozygous samples from a variety of sources and can be applied for tissue typing, disease susceptibility studies and forensic medicine.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8456438     DOI: 10.1111/j.1399-0039.1993.tb01970.x

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  33 in total

1.  Characterization of the T cell recognition of hepatitis B surface antigen (HBsAg) by good and poor responders to hepatitis B vaccines.

Authors:  I Desombere; Y Gijbels; A Verwulgen; G Leroux-Roels
Journal:  Clin Exp Immunol       Date:  2000-12       Impact factor: 4.330

2.  Non-responsiveness to hepatitis B surface antigen vaccines is not caused by defective antigen presentation or a lack of B7 co-stimulation.

Authors:  I Desombere; T Cao; Y Gijbels; G Leroux-Roels
Journal:  Clin Exp Immunol       Date:  2005-04       Impact factor: 4.330

3.  Simultaneous genotyping of DRB1/3/4/5 loci by oligonucleotide microarray.

Authors:  Ye Bang-Ce; Chu Xiaohe; Fan Ye; Li Songyang; Yin Bincheng; Zuo Peng
Journal:  J Mol Diagn       Date:  2005-11       Impact factor: 5.568

4.  HLA class II polymorphism: protective or risk factors to breast cancer in Tunisia?

Authors:  Amal Baccar Harrath; Besma Yacoubi Loueslati; Wafa Troudi; Slama Hmida; Syrine Sedkaoui; Amel Dridi; Afef Jridi; Farhat Ben Ayed; Khaled Ben Rhomdhane; Amel Ben Ammar Elgaaied
Journal:  Pathol Oncol Res       Date:  2006-06-24       Impact factor: 3.201

5.  Antigen-specific immune responses to influenza vaccine in utero.

Authors:  Deepa Rastogi; Chaodong Wang; Xia Mao; Cynthia Lendor; Paul B Rothman; Rachel L Miller
Journal:  J Clin Invest       Date:  2007-06       Impact factor: 14.808

6.  Construction of microarrays for genotyping of DQA using unmodified 45-mer oligonucleotide.

Authors:  Bin-Cheng Yin; Fei Yue; Bang-Ce Ye
Journal:  Mol Biotechnol       Date:  2007-06       Impact factor: 2.695

7.  HLA-DR gene frequencies in a Zaïrean population with particular reference to rheumatic diseases.

Authors:  K Mbayo; J M Mbuyi-Muamba; L Hallé; D Salmon; C Martageix; F Castellano; C Kaplan; Z Lurhuma
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

8.  The prevalences of some rheumatic diseases in western Turkey: Havsa study.

Authors:  Necati Cakır; Ömer Nuri Pamuk; Emine Derviş; Neşe Imeryüz; Haşim Uslu; Ömer Benian; Edip Elelçi; Genco Erdem; Fatma Oğuz Sarvan; Mustafa Senocak
Journal:  Rheumatol Int       Date:  2011-01-13       Impact factor: 2.631

Review 9.  Current methods and challenges in the comprehensive characterization of human pluripotent stem cells.

Authors:  Joanna S T Asprer; Uma Lakshmipathy
Journal:  Stem Cell Rev Rep       Date:  2015-04       Impact factor: 5.739

10.  HLA-DR typing for kidney transplants: advantage of polymerase chain reaction with sequence specific primers in a routine hospital laboratory.

Authors:  C Lynas; N J Hurlock; J A Copplestone; A G Prentice; R J McGonigle
Journal:  J Clin Pathol       Date:  1994-07       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.